As per MRFR analysis, the India Geographic Atrophy GA Market Size was estimated at 1.35 (USD Billion) in 2024.The India Geographic Atrophy GA Market Industry is expected to grow from 1.75(USD Billion) in 2025 to 3 (USD Billion) by 2035. The India Geographic Atrophy GA Market CAGR (growth rate) is expected to be around 5.022% during the forecast period (2025 - 2035).
The India Geographic Atrophy (GA) market is experiencing significant trends driven by the growing elderly population, as India has one of the largest demographics of senior citizens globally. This demographic shift leads to an increased prevalence of age-related macular degeneration (AMD), which includes geographic atrophy, thereby creating a substantial need for effective treatment options. The government’s initiatives towards enhancing eye care infrastructure and promoting awareness about eye diseases further support the market's development.
Key market drivers include advancements in research and development for new therapies targeting geographic atrophy.Pharmaceutical companies are increasingly investing in innovative treatment modalities, including gene therapies and injectable medications, which represent a shift in how eye diseases are treated. Furthermore, partnerships between governmental health agencies and private sector players are creating synergies that facilitate better access to cutting-edge treatments for patients across the country.
Opportunities in the India market can be captured by focusing on telemedicine and digital health solutions that provide remote consultation and monitoring for patients suffering from geographic atrophy. The rise of health tech platforms presents a chance to improve patient engagement and adherence to treatment regimens.Similarly, educational initiatives aimed at healthcare professionals about the importance of early diagnosis can stimulate market growth.
Trends in recent times show an uptick in clinical trials and research focused on geographic atrophy within India, supported by a strong regulatory framework. This active participation in research indicates the market's potential resulting in the introduction of newer therapies. Overall, these developments align with the broader goal of enhancing vision care as part of India's healthcare agenda.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The increasing prevalence of Geographic Atrophy (GA) is primarily driven by the aging population in India. According to the Ministry of Statistics and Programme Implementation, the percentage of the elderly population in India is projected to nearly double from 8.6% in 2011 to about 19% by 2050. As age is a significant risk factor for GA, with studies showing that the incidence of age-related macular degeneration (AMD), which can lead to GA, increases exponentially with age, this demographic shift is particularly concerning.
Organizations such as the All India Ophthalmological Society are actively working on awareness programs revolving around age-related eye diseases, urging the healthcare system to prepare for a rising number of GA cases. This increase in aging individuals will likely contribute to the growth of the India Geographic Atrophy GA Market Industry significantly.
Technological advancements have led to more accurate and earlier diagnosis of Geographic Atrophy, thereby positively influencing the India Geographic Atrophy GA Market Industry. The introduction of high-resolution imaging techniques such as Optical Coherence Tomography has enabled healthcare professionals to detect GA in its early stages. According to research published in the Indian Journal of Ophthalmology, early identification of GA can significantly improve patient management and treatment outcomes.
The adoption of these technologies is encouraged at public health facilities by the National Programme for Control of Blindness and Visual Impairment, which highlights the foreseeable advancement in market growth from enhanced diagnostics.
The heightened focus on Research and Development (R&D) for GA treatments is driving growth in the India Geographic Atrophy GA Market Industry. Noteworthy pharmaceutical companies, including Novartis and Roche, are investing heavily in clinical trials and innovative therapies aimed at treating GA. As per the Department of Biotechnology, the Government of India has initiated efforts to fund biotech innovations, including new treatment methodologies for retinal diseases.
With the rising incidence of GA and subsequent increase in funding for R&D initiatives, the market is poised for expansion, highlighting the importance of a collaborative approach among government, industries, and research institutions.
The Age Group segment of the India Geographic Atrophy GA Market reveals critical insights surrounding the elderly population, driven largely by the increasing prevalence of age-related eye diseases in the nation. As the population aged 60 and over continues to expand significantly due to better healthcare and living conditions, this demographic represents a large portion of the market. Individuals above 60 years old are particularly vulnerable as they experience a higher risk of geographic atrophy, making them a pivotal focus for healthcare providers and market stakeholders.
The challenge of increasing age-related ocular conditions places emphasis on the necessity for early diagnosis, effective treatment solutions, and ongoing awareness campaigns targeted at this age group.
When delving deeper into the segment of those aged above 75 years, we observe that this category presents unique challenges and opportunities. This age group often faces compounded health issues, including comorbidities that can complicate the treatment of geographic atrophy. Moreover, the significant insights regarding lifestyle changes and dietary habits affecting ocular health further emphasize the need for targeted interventions. By acknowledging these factors, stakeholders can develop tailored approaches to education and access to care that are crucial for individuals in this age category.
Domestically, the healthcare policies and initiatives aimed at elderly care set the stage for market expansion, particularly focusing on screening programs and geriatric eye care facilities. The increasing awareness about vision impairment and its effects on the quality of life for older adults propels the demand for innovative treatment options and palliative care. Moreover, regional advancements in technology and telemedicine open doors for remote consultations, enabling better access to specialized care for older adults, especially in rural regions of India.
In summary, the insights derived from the Age Group segmentation within the India Geographic Atrophy GA Market illustrate a clear connection between age and the prevalence of geographic atrophy, highlighting the significance of targeted healthcare strategies. The combination of the growing elderly population, coupled with the rising incidence of age-related eye disorders, establishes a compelling case for focused research, development, and comprehensive healthcare solutions tailored to these age groups. This is further bolstered by an evolving healthcare infrastructure aimed at improving access and quality of care for older adults, thereby enabling better management of geographic atrophy and enhancing the quality of life for this vulnerable population.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Diagnosis segment of the India Geographic Atrophy GA Market is witnessing substantial growth, driven by the increasing prevalence of age-related macular degeneration and rising awareness about early diagnosis. As technology advances, methods for diagnosis such as Fundus Autofluorescence, Optical Coherence Tomography Angiography, and Multifocal Electroretinography are gaining prominence.
Fundus Autofluorescence plays a crucial role in visualizing retinal health by detecting lipofuscin accumulation, which is often associated with Geographic Atrophy.On the other hand, Optical Coherence Tomography Angiography offers high-resolution imaging of blood flow in the retina, facilitating better assessment of neovascularization. Multifocal Electroretinography is significant for evaluating retinal function across distinct regions, thereby supporting precise diagnosis and management of the disease.
The integration of these technologies is essential for accurate diagnostics, ultimately enabling timely interventions and better patient outcomes. Given that India is home to a rapidly growing elderly population, the demand for advanced diagnostic solutions to detect geographic atrophy is expected to rise, aligning with the overall growth trajectory of the India Geographic Atrophy GA Market.
The Therapeutic Agents Clinical Phase segment of the India Geographic Atrophy GA Market is a crucial component in the development of treatments aimed at this eye condition. As India faces a growing population at risk for age-related vision problems, clinical advancement in this segment is imperative. Among the phases, Late-Stage candidates are particularly significant, reflecting trials that are nearing the market launch and are likely to influence treatment accessibility for patients across India.
Meanwhile, Phase II and Phase I studies are essential for evaluating the efficacy and safety of potential therapies, demonstrating a rigorous evaluation process that instills confidence in treatment outcomes.The Pre-Clinical Stage and Discovery Candidates play a pivotal role in fostering innovation, where novel therapeutic approaches are being explored, aligning with India's increasing investment in Research and Development.
This segment is vital for driving advancements, with the growing emphasis on tailored patient care strategies, which are becoming a trend in the healthcare industry. As the country prioritizes healthcare improvements, the strategic focus on this clinical phase may well lead to significant breakthroughs in managing Geographic Atrophy, ultimately transforming patient care landscape in India.
The India Geographic Atrophy GA Market is currently undergoing significant developments as it grapples with the challenges posed by age-related macular degeneration, a leading cause of vision loss. This market is characterized by a blend of established players and emerging companies focusing on innovative therapeutic solutions. The competitive landscape is becoming increasingly dynamic, driven by the necessity for effective treatment options and the growing patient population affected by this condition. Companies are investing in research and development to bring forth novel therapies while also exploring collaborations and partnerships.
The regulatory environment, along with market access hurdles and reimbursement frameworks, plays a pivotal role in shaping the strategies of firms operating in this space. Understanding the competitive insights within this market is essential for companies to navigate the complexities and identify potential opportunities.Santen Pharmaceutical has made a notable mark in the India Geographic Atrophy GA Market by leveraging its extensive expertise in ophthalmic pharmaceuticals. The company is recognized for its commitment to improving patient outcomes through innovative treatments.
Santen's strengths lie in its dedicated focus on research and development, enabling it to stay at the forefront of advancements in therapies targeting geographic atrophy. The company has established a strong presence in the Indian market, thanks in part to its strategic collaborations with local healthcare providers and stakeholders. By tailoring its product offerings to meet the specific needs of the Indian population, Santen has been able to create a solid foundation of trust and reliability among healthcare professionals, enhancing its competitive edge in this evolving landscape.
Aurion Biotech is also a significant player in the India Geographic Atrophy GA Market, focusing on ground-breaking therapeutic solutions aimed at retinal diseases. Known for its research-driven approach, Aurion Biotech has developed several key products specifically designed to address the unmet needs of patients suffering from geographic atrophy. The company's strengths include its focus on innovation and its commitment to advancing the understanding of retinal health through extensive clinical studies. In India, Aurion Biotech enjoys a favorable market presence due to its relationships with ophthalmologists and healthcare facilities, allowing for better distribution and access to its therapies. The company's strategic initiatives, including potential mergers and acquisitions, aim to bolster its market position and expand its portfolio of solutions tailored for the Indian demographic. This combination of innovative product development and strategic market engagement enhances Aurion Biotech's competitiveness in the Indian market for geographic atrophy treatment.
The India Geographic Atrophy (GA) Market is witnessing significant developments, particularly with companies such as Santen Pharmaceutical and Novartis, are advancing their research initiatives for treatments targeting this condition. Current affairs indicate that Aurion Biotech has made strides in clinical trials for its GA therapies, further indicating a burgeoning interest in the sector. An important merger was noted in August 2023 when Neurotech acquired a minority stake in a research venture with Croma Pharma, aiming to innovate therapeutic solutions for GA.
In terms of market dynamics, Bausch + Lomb and Allergan are actively enhancing their product pipelines to capture a larger share of the growing market, propelled by an increasing population with retina-related disorders in India. The Indian government's efforts to improve healthcare infrastructure are also catalyzing advancements in the GA market, facilitating better access to innovative treatments. Over the past two years, significant investments have poured into research and development by Bayer and Regeneron Pharmaceuticals, reflecting an ongoing commitment to address the unmet medical needs of GA patients.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.35(USD Billion) |
| MARKET SIZE 2024 | 1.75(USD Billion) |
| MARKET SIZE 2035 | 3.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.022% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Santen Pharmaceutical, Aurion Biotech, Croma Pharma, Ophthotech, Novartis, Allergan, Neurotech, Bayer, Kowa Company, Roche, Bausch + Lomb, Kiorpharma, Grey Wolf Therapeutics, Regeneron Pharmaceuticals, Alcon |
| SEGMENTS COVERED | Age Group, Diagnosis, Therapeutic Agents Clinical Phase |
| KEY MARKET OPPORTUNITIES | Rising elderly population prevalence, Increased awareness and diagnosis, Innovative treatment development, Growing healthcare infrastructure, Investment in clinical trials and research |
| KEY MARKET DYNAMICS | increasing elderly population, rising prevalence of GA, advancements in treatment options, growing awareness and diagnosis, supportive regulatory environment |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India Geographic Atrophy GA Market is expected to be valued at 3.0 USD Billion by 2035.
The market size of the India Geographic Atrophy GA Market in 2024 was valued at 1.75 USD Billion.
The expected CAGR for the India Geographic Atrophy GA Market from 2025 to 2035 is 5.022%.
The age group of Above 60 Years significantly contributes to the India Geographic Atrophy GA Market.
The projected market size for the Above 60 Years age group in 2035 is 1.8 USD Billion.
The projected market size for the Above 75 Years age group in 2035 is 1.2 USD Billion.
Major players in the market include Santen Pharmaceutical, Aurion Biotech, Croma Pharma, and Novartis.
Key growth drivers include the increasing elderly population and advancements in treatment options.
Challenges in the market include high treatment costs and limited awareness about Geographic Atrophy.
The anticipated market growth rate for the India Geographic Atrophy GA Market is projected to be steady at 5.022% CAGR through 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
